RPL 554

Drug Profile

RPL 554

Alternative Names: RPL-554

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Antiallergics; Antiasthmatics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma; Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Allergic rhinitis

Most Recent Events

  • 07 Sep 2017 Positive topline efficacy, safety and pharmacodynamics data from a phase IIa trial in Chronic obstructive pulmonary disease released by Verona Pharma
  • 09 Aug 2017 Verona Pharma completes enrolment in phase I trial for Chronic obstructive pulmonary disease (In volunteers) in USA
  • 08 Aug 2017 Verona Pharma plans a phase II trial for Chronic obstructive pulmonary disease (Adjunctive treatment) in USA in 2H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top